ONC201 in Recurrent or Metastatic Type II Endometrial Cancer Endometrial Cancer
Study sponsor: Jazz Pharmaceuticals
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2023-01-19Actual
Enrollment · participants27Actual
Source updated2024-12-24Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.